Type 2 diabetes and the related metabolic syndrome (a cluster of abnormalities including insulin resistance, obesity, hyperlipidaemia, and hypertension) are increasing in prevalence, due to an ageing population and to lifestyle factors, notably diet and exercise. Diabetes causes debilitating long-term complications, while the components of the metabolic syndrome are key risk factors for cardiovascular disease. The AMP-activated protein kinase (AMPK) system monitors the energy status of cells, is activated by exercise or low glucose, and acts as a "metabolic master switch" turning catabolic and anabolic pathways on and off. The same pathways are altered in metabolic syndrome, suggesting that AMPK might be playing a role in its development. Our proposal brings together a multidisciplinary group of leading European researchers, and should provide the knowledge base and tools for development of new therapeutic regimes.
Funding SchemeCSC - Cost-sharing contracts
W12 0NN London